NEOS Investment Management LLC Buys 8,890 Shares of Cencora, Inc. $COR

NEOS Investment Management LLC grew its stake in shares of Cencora, Inc. (NYSE:COR) by 97.5% during the 3rd quarter, Holdings Channel reports. The firm owned 18,007 shares of the company’s stock after buying an additional 8,890 shares during the period. NEOS Investment Management LLC’s holdings in Cencora were worth $5,628,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC raised its position in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Cloud Capital Management LLC acquired a new position in shares of Cencora during the 3rd quarter worth about $31,000. Westside Investment Management Inc. raised its holdings in shares of Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after purchasing an additional 70 shares during the period. Copia Wealth Management lifted its stake in Cencora by 505.0% in the 3rd quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after purchasing an additional 101 shares during the last quarter. Finally, Caldwell Trust Co acquired a new stake in Cencora in the 2nd quarter valued at about $46,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,220 shares of company stock valued at $5,282,867 over the last 90 days. Corporate insiders own 0.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Wells Fargo & Company boosted their price target on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. TD Cowen lifted their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Evercore cut their price objective on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, UBS Group lifted their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: The MWI–Covetrus merger values Cencora’s animal-health unit at ~$3.5B, providing proceeds and a clearer strategic focus on drug distribution — investors see this as de-risking and simplifying the company. Reuters: Cencora’s animal health unit to merge with Covetrus Philadelphia Business Journal: Cencora makes $3.5B deal
• Positive Sentiment: Coverage highlights that the divestiture lets Cencora refocus capital and management on higher-margin, core drug distribution operations — a narrative that can support multiple expansion. MSN: Cencora to refocus on drug distribution
• Neutral Sentiment: Analysts currently rate Cencora around a “moderate buy,” so the market reaction may be in line with expectations rather than a surprise re-rating. American Banking News: Consensus Moderate Buy
• Neutral Sentiment: Options activity suggests some traders are positioning for bigger moves, which can increase short-term volatility but doesn’t change fundamentals. Zacks: Options market activity
• Negative Sentiment: The deal reduces diversification and recurring revenue from animal health; proceeds may be one-time and the company still faces high leverage and integration/execution risk if transaction terms are complex. TMCNet: Covetrus and MWI Animal Health to Merge

Cencora Price Performance

COR opened at $360.50 on Thursday. Cencora, Inc. has a fifty-two week low of $240.10 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a 50-day moving average of $348.82 and a 200 day moving average of $330.12. The firm has a market cap of $70.13 billion, a P/E ratio of 43.33, a PEG ratio of 1.66 and a beta of 0.68.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the prior year, the company earned $3.73 EPS. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.